Neoadjuvant PD-L1 Inhibitor Plus Anlotinib for Kidney Preservation in Complex Renal Cell Carcinoma
Clinical trial NCT07602101 · NOT_YET_RECRUITING
Trial details
- NCT number
- NCT07602101
- Sponsor
- RenJi Hospital
- Status
- NOT_YET_RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2026-05-31
- Primary completion
- 2027-12-31
- Enrollment
- 33
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.